IMVT - Immunovant: Speculative Biotech With Proven Class Of Drugs Targeting FcRn Pathway

• Plans to initiate phase 3 study using batoclimab for the treatment of patients with myasthenia gravis expected 1st half of 2022.
• Two additional indications in the pipeline will be announced in August of 2022.
• Goal to choose two additional indications with the use of batoclimab to move forward with in two late-stage studies in 2022.
• The targeting of the FcRn pathway is a proven model with Argenx having received regulatory approvals for Vyvgart in myasthenia gravis and Janssen advancing nipocalimab for the same indication in a phase 3 study.

For further details see: